Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 8/20 | 0.58 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 5/20 | 0.46 |
| ▸ | MAOB | P27338 | 5/20 | 0.46 |
| ▸ | PKM | P14618 | 3/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL688889 | 0.83 | CES1 (0.56) | KIF11CES1MAOB | |
| SCHEMBL28956489 | 0.82 | KIF11 (0.73) | KIF11CES1MAPTSMN1; SMN2MAOA | |
| SCHEMBL30122307 | 0.82 | KIF11 (0.73) | KIF11CES1MAPTSMN1; SMN2MAOA | |
| SCHEMBL17260111 | 0.82 | CES1 (0.46) | KIF11CES1MAPTSMN1; SMN2 | |
| SCHEMBL3186685 | 0.80 | PDE3B (0.56) | MAPTMAOAMAOBPKM | |
| SCHEMBL3310995 | 0.80 | KIF11 (0.70) | KIF11CES1MAPTSMN1; SMN2MAOA | |
| SCHEMBL17785603 | 0.79 | KIF11 (0.57) | KIF11MAOAMAOB | |
| SCHEMBL7376776 | 0.78 | CES1 (0.51) | KIF11CES1MAPTSMN1; SMN2MAOA | |
| SCHEMBL6585388 | 0.77 | MAOB (0.60) | MAPTSMN1; SMN2MAOAMAOB | |
| SCHEMBL9024780 | 0.77 | KIF11 (0.67) | KIF11MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3143014-B1 | CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2018-10-24 | — | — | EP | disclosed |
| US-9931319-B2 | Carboxamide derivatives | NOVARTIS AG (CH) | 2018-04-03 | — | — | US | disclosed |
| EP-3143014-A1 | CARBOXAMIDE DERIVATIVES | Novartis AG (CH) | 2017-03-22 | — | — | EP | disclosed |
| US-20170000770-A1 | CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2017-01-05 | — | — | US | disclosed |
| US-9403833-B2 | Carboxamide derivatives | NOVARTIS AG (CH) | 2016-08-02 | — | — | US | disclosed |
| WO-2015177646-A1 | CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2015-11-26 | — | — | WO | disclosed |
| US-20150329549-A1 | CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2015-11-19 | — | — | US | disclosed |
| US-20110212891-A1 | AZEPINONE DERIVATIVES | MSD K.K. | 2011-09-01 | — | — | US | disclosed |
| EP-2358735-A1 | AZEPINONE DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010056496-A1 | AZEPINONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170000770-A1 | CARBOXAMIDE DERIVATIVES | SIRT5, SIRT7, ADCY5 | KIF11 3651/4885CES1 208/4885MAPT 2753/4885 |
| US-20110212891-A1 | AZEPINONE DERIVATIVES | AZI2, NDUFS3, RPS4Y1 | KIF11 3744/4885CES1 3389/4885MAPT 4687/4885 |
| US-20150329549-A1 | CARBOXAMIDE DERIVATIVES | CNR2, SIRT7, SLC5A2 | KIF11 3450/4885CES1 363/4885MAPT 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.